EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 130 filers reported holding EXELIXIS INC in Q3 2014. The put-call ratio across all filers is 0.76 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $2,819,176 | -56.9% | 125,464 | -54.5% | 0.02% | -56.5% |
Q1 2024 | $6,539,917 | +49.3% | 275,597 | +51.0% | 0.05% | +39.4% |
Q4 2023 | $4,378,990 | -9.2% | 182,534 | -17.3% | 0.03% | -19.5% |
Q3 2023 | $4,820,744 | +11.3% | 220,629 | -2.6% | 0.04% | +20.6% |
Q2 2023 | $4,330,173 | -5.5% | 226,592 | -4.0% | 0.03% | -12.8% |
Q1 2023 | $4,580,857 | +20.8% | 236,005 | -0.2% | 0.04% | +18.2% |
Q4 2022 | $3,791,471 | +1.9% | 236,376 | -0.4% | 0.03% | -2.9% |
Q3 2022 | $3,721,000 | -25.7% | 237,332 | -1.3% | 0.03% | -15.0% |
Q2 2022 | $5,006,000 | -12.2% | 240,454 | -4.4% | 0.04% | +17.6% |
Q1 2022 | $5,704,000 | +18.1% | 251,597 | -4.8% | 0.03% | +36.0% |
Q4 2021 | $4,830,000 | -32.2% | 264,252 | -21.6% | 0.02% | -41.9% |
Q3 2021 | $7,122,000 | +23.8% | 336,860 | +6.7% | 0.04% | +26.5% |
Q2 2021 | $5,754,000 | -10.8% | 315,781 | +10.5% | 0.03% | -19.0% |
Q1 2021 | $6,454,000 | +13.4% | 285,705 | +0.7% | 0.04% | +16.7% |
Q4 2020 | $5,692,000 | -6.9% | 283,640 | +13.5% | 0.04% | -18.2% |
Q3 2020 | $6,112,000 | -14.2% | 249,993 | -16.7% | 0.04% | -20.0% |
Q2 2020 | $7,126,000 | +55.6% | 300,157 | +12.8% | 0.06% | +19.6% |
Q1 2020 | $4,581,000 | -14.3% | 266,024 | -12.3% | 0.05% | +15.0% |
Q4 2019 | $5,348,000 | +42.3% | 303,478 | +42.8% | 0.04% | +33.3% |
Q3 2019 | $3,759,000 | -19.5% | 212,531 | -2.8% | 0.03% | -21.1% |
Q2 2019 | $4,671,000 | -20.1% | 218,593 | -11.0% | 0.04% | -20.8% |
Q1 2019 | $5,848,000 | +21.9% | 245,724 | +0.7% | 0.05% | +17.1% |
Q4 2018 | $4,799,000 | -26.5% | 243,958 | -33.7% | 0.04% | -4.7% |
Q3 2018 | $6,525,000 | -17.0% | 368,222 | +0.8% | 0.04% | -17.3% |
Q2 2018 | $7,865,000 | +63.2% | 365,394 | +67.9% | 0.05% | +333.3% |
Q1 2018 | $4,819,000 | -20.7% | 217,565 | +8.8% | 0.01% | -14.3% |
Q4 2017 | $6,078,000 | -12.4% | 199,958 | -30.2% | 0.01% | -12.5% |
Q3 2017 | $6,937,000 | -1.6% | 286,284 | -0.0% | 0.02% | -15.8% |
Q2 2017 | $7,051,000 | +34.6% | 286,330 | +18.5% | 0.02% | +35.7% |
Q1 2017 | $5,238,000 | +34.4% | 241,711 | -7.5% | 0.01% | +27.3% |
Q4 2016 | $3,898,000 | +0.9% | 261,433 | -13.5% | 0.01% | -8.3% |
Q3 2016 | $3,864,000 | +33.6% | 302,121 | -18.4% | 0.01% | +33.3% |
Q2 2016 | $2,892,000 | +4973.7% | 370,240 | +3540.5% | 0.01% | – |
Q4 2015 | $57,000 | +3.6% | 10,170 | -30.0% | 0.00% | – |
Q2 2015 | $55,000 | -3.5% | 14,521 | -34.0% | 0.00% | – |
Q1 2015 | $57,000 | +90.0% | 22,013 | +6.5% | 0.00% | – |
Q4 2014 | $30,000 | -95.3% | 20,661 | -95.0% | 0.00% | -100.0% |
Q3 2014 | $633,000 | -50.0% | 413,407 | +10.7% | 0.00% | -33.3% |
Q2 2014 | $1,266,000 | -38.0% | 373,386 | -35.3% | 0.00% | -50.0% |
Q1 2014 | $2,042,000 | -36.3% | 576,892 | +10.3% | 0.01% | -40.0% |
Q4 2013 | $3,206,000 | -4.6% | 522,924 | -9.4% | 0.01% | -16.7% |
Q3 2013 | $3,361,000 | +4842.6% | 577,474 | +3783.7% | 0.01% | – |
Q2 2013 | $68,000 | – | 14,869 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 15,001,073 | $320,572,000 | 64.48% |
Sargent Investment Group, LLC | 432,125 | $9,235,000 | 4.22% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 443,534 | $9,483,000 | 3.52% |
Bellevue Group AG | 3,878,800 | $82,890,000 | 1.42% |
CAPITAL MANAGEMENT CORP /VA | 237,855 | $5,083,000 | 1.40% |
Orbimed Advisors | 3,912,900 | $83,619,000 | 1.30% |
Portolan Capital Management | 540,590 | $11,552,000 | 1.24% |
TEALWOOD ASSET MANAGEMENT INC | 139,347 | $2,978,000 | 1.21% |
Signition LP | 84,120 | $1,798,000,000 | 1.18% |
Penn Capital Management Company, LLC | 529,630 | $11,318,000 | 1.12% |